Insight Molecular Diagnostics (IMDX) Receivables (2020 - 2026)

Insight Molecular Diagnostics has disclosed Receivables across 7 years of filings, most recently posting $157000.0 for Q1 2026.

• Receivables for Q1 2026 came in at $157000.0, down 95.56% year-over-year; the trailing twelve-month figure through Mar 2026 was $157000.0 (down 95.56% YoY), and the FY2025 annual result was $1.1 million, down 29.5% from the prior year.
• Receivables came in at $157000.0 for Q1 2026 at Insight Molecular Diagnostics, down from $1.1 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $3.5 million in Q1 2025 to a low of $85000.0 in Q2 2024.
• The 5-year median for Receivables is $593000.0 (2023), against an average of $1.1 million.
• Across the five-year window, Receivables soared 2098.76% in 2025 and slumped 95.56% in 2026, its largest moves.
• Insight Molecular Diagnostics' Receivables stood at $1.4 million in 2022, then sank by 65.07% to $489000.0 in 2023, then surged by 227.2% to $1.6 million in 2024, then dropped by 29.5% to $1.1 million in 2025, then sank by 86.08% to $157000.0 in 2026.
• The last three Receivables figures came in at $157000.0 (Q1 2026), $1.1 million (Q4 2025), and $258000.0 (Q3 2025), per Business Quant data.